Physician profile
Robert C Hinkle
NPI 1023032422
$19,491.52
in general payments reported to CMS, 2019-2025
15 companies · $323 in 2025
The $323 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,031 · 2020: $2,735 · 2021: $401 · 2022: $542 · 2023: $7,232 · 2024: $227 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,825 · Food and Beverage: $858 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,825.00 |
| Food and Beverage | $857.67 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,088.14 | 2019-2020 | |
| Glaxosmithkline, LLC. | $7,826.93 | 2019-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $352.18 | 2021-2025 | Entyvio |
| Jazz Pharmaceuticals INC. | $212.33 | 2019-2024 | |
| Insmed, INC. | $126.66 | 2019 | |
| Amarin Pharma, INC. | $125.00 | 2020 | |
| Inspire Medical Systems, INC. | $124.51 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $123.47 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $121.83 | 2019 | |
| Janssen Pharmaceuticals, INC | $119.72 | 2019 | |
| Intuitive Surgical, INC. | $84.42 | 2022 | |
| Ethicon INC. | $76.11 | 2021 | |
| Viatris Specialty LLC | $53.66 | 2025 | Yupelri |
| Inogen, INC. | $35.76 | 2024-2025 | |
| Genzyme Corporation | $20.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hinkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.